News

The US Preventive Services Task Force (Task Force) issued its final recommendation on vitamin D and calcium supplements for the prevention of fractures, of which there are several individual recommendations for people who do not live in assisted living or nursing homes.

Processing a prescription through an electronic ordering system decreases the likelihood of error on that order by 48%, and avert more than 17 million such incidents in US hospitals in 1 year alone, according to research published online in the Journal of the American Medical Informatics Association.

Gonorrhea, caused by the bacterium, Neisseria gonorrhoeae, continues to be a major US public health problem in terms of its prevalence as well as the lack of effective treatments available.

A study by Norwegian researchers has shown that the use of folic acid supplements around the time of conception may lower the risk of autism in children. The study was published in the February 13, 2013, issue of The Journal of the American Medical Association.

The National Breast Cancer Coalition recently awarded a nearly $200,000 seed grant to two researchers who will study the viral connection to breast cancer. The research will assess the infectious agent in breast tumors compared to normal breast tissue, which could lead to a preventive vaccine.

The federal government and states will face a number of challenges upon establishing and operating federally facilitated health insurance exchanges.

Utah seeks hybrid exchange

Utah governor hopes to gain federal certification for the state's insurance exchange, which would ideally use a hybrid exchange model.

Although generally satisfied with global cancer research progress, the public believes it takes too long for new cancer drugs to reach patients.

FDA has approved pomalidomide (Pomalyst, Celgene) to treat patients who have received at least 2 prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Despite availability of many therapies indicated for bowel disorders, there is still an unmet need and heterogeneity among these patients, necessitating availability of a wide variety of therapeutics. Awareness of potential new products, their key benefits, and where they may fit into the treatment paradigm will be important when making decisions impacting patients and physicians, according to new analysis.